423 related articles for article (PubMed ID: 11029467)
1. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1.
Delgado M; Ganea D
J Biol Chem; 2001 Jan; 276(1):369-80. PubMed ID: 11029467
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.
Delgado M; Ganea D
J Immunol; 2001 Jan; 166(2):1028-40. PubMed ID: 11145682
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun.
Delgado M; Munoz-Elias EJ; Kan Y; Gozes I; Fridkin M; Brenneman DE; Gomariz RP; Ganea D
J Biol Chem; 1998 Nov; 273(47):31427-36. PubMed ID: 9813054
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 Oct; 297(5):1181-5. PubMed ID: 12372411
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages.
Delgado M; Ganea D
J Neuroimmunol; 2000 Oct; 110(1-2):97-105. PubMed ID: 11024538
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
8. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
Delgado M; Ganea D
J Immunol; 2001 Jul; 167(2):966-75. PubMed ID: 11441105
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
Delgado M; Ganea D
J Immunol; 2000 Sep; 165(6):3051-7. PubMed ID: 10975815
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
Delgado M; Leceta J; Ganea D
J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation.
Delgado M; Ganea D
J Biol Chem; 1999 Nov; 274(45):31930-40. PubMed ID: 10542221
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
[TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
[TBL] [Abstract][Full Text] [Related]
16. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.
Delgado M; Leceta J; Abad C; Martinez C; Ganea D; Gomariz RP
J Neuroimmunol; 1999 Sep; 99(1):61-71. PubMed ID: 10496178
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
18. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
19. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
Taupenot L; Mahata SK; Wu H; O'Connor DT
J Clin Invest; 1998 Feb; 101(4):863-76. PubMed ID: 9466982
[TBL] [Abstract][Full Text] [Related]
20. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
